
    
      This was a multicenter, open-label, randomized, active controlled, parallel group chronic
      safety study of arformoterol 50 mcg once daily over a period of 12 months in subjects with
      COPD. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was
      acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed
      to Sunovion Pharmaceuticals Inc.
    
  